GlassScriptPhysician profile
Bradley M Leonard
NPI 1932156213
$9,983.11
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,588 · 2020: $1,715 · 2021: $2,206 · 2022: $2,617 · 2023: $522 · 2024: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,064.26 | 2019-2024 | Aveir, Gallant, Assurity |
| Pfizer INC. | $1,018.98 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $978.29 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $799.46 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $747.71 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $697.81 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $674.38 | 2019-2023 | Jardiance |
| Amgen INC. | $539.53 | 2019-2023 | Repatha |
| Medtronic, INC. | $528.58 | 2022-2024 | Corevalve Evolut R, Onyx Frontier, Abre |
| Merck Sharp & Dohme LLC | $432.67 | 2021-2023 | Verquvo |
| Amarin Pharma, INC. | $374.34 | 2019-2022 | |
| Heartflow, INC. | $251.12 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $225.00 | 2019-2023 | Onpattro |
| Chiesi USA, INC. | $219.59 | 2019-2022 | |
| Biotronik INC. | $192.77 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $169.50 | 2019-2023 | Watchman Access System |
| Novo Nordisk INC | $153.51 | 2021-2023 | Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $132.01 | 2019-2021 | |
| Vifor Pharma, INC. | $121.64 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $111.93 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $104.56 | 2019-2022 | |
| Astellas Pharma US INC | $101.36 | 2019-2021 | |
| Esperion Therapeutics, INC. | $83.13 | 2020-2022 | |
| Edwards Lifesciences Corporation | $46.86 | 2019-2022 | |
| Portola Pharmaceuticals, LLC | $33.33 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $31.00 | 2019 | |
| Acist Medical Systems, INC. | $29.92 | 2019 | |
| Tactile Systems Technology INC | $24.93 | 2019-2021 | |
| Gilead Sciences, INC. | $19.02 | 2019 | |
| Althera Pharmaceuticals LLC | $18.06 | 2022 | |
| Angiodynamics, INC. | $17.22 | 2022 | |
| Bardy Diagnostics, INC. | $15.00 | 2019 | |
| Atricure, INC. | $13.88 | 2020 | |
| Siemens Medical Solutions USA, INC. | $11.76 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$612,850.88 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Leonard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.